Join a Clinical Trial

The purpose of this study is to evaluate whether levetiracetam reduces subclinical (clinically silent) seizure activity and/or improves cognition in a subset of people with Alzheimer’s disease (AD) who exhibit epileptiform activity.

The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (the protein that forms plaques in the brains of people with Alzheimer’s disease) as compared with placebo in subjects with preclinical AD.

LMTM is postulated to dissolve, as well as prevent, further formation of tau and TDP-43 aggregates that are thought to be neurotoxic in frontotemporal lobar degeneration syndromes. The purpose of this study is to evaluate whether LMTM is efficacious, safe and well-tolerated in subjects with bvFTD.

Most dementia care today is crisis-oriented. To break away from the cycle of stressful and costly issues that arise from a reactive approach, the Care Ecosystem will emphasize coordinated, continuous and personalized care. This proactive care model aims to improve patient satisfaction and caregiver health, and reduce avoidable emergency room visits, hospitalizations, or institutionalization.

Tau is a microtubule-associated protein, and abnormal tau function has been proposed to play a role in the development and progression of primary four repeat tauopathies, CBS and PSP. TPI-287 is a stabilizer of microtubule dynamics, and the stabilization of microtubules is hypothesized to compensate for the loss of tau function in primary four-repeat tauopathies. The purpose of this study is to determine the safety and tolerability of intravenous (IV) infusions of TPI-287 in patients with four-repeat tauopathies (4RT), CBS or PSP.

The purpose of this study is to explore the benefits of regular physical activity to adult women and men providing care to family members who have been diagnosed with Alzheimer’s disease or dementia.

The purpose of this study is to learn more about how a behavioral intervention that aims to increase positive affect can affect stress level, improve mood, and lessen the perceived burden of family caregiving for those who care for a person with dementia.

The production and deposition of amyloid plaques in the brain is thought to contribute to the development and progression of Alzheimer’s disease (AD). Solanezumab is hypothesized to reduce accumulation of amyloid plaques and thus slow the progression of AD. The primary purpose of the study is to determine if Solanezumab will slow cognitive and functional decline in participants with mild AD.

The purpose of this study is to evaluate the efficacy and safety of Crenezumab, an amyloid antibody, in patients with mild to moderate Alzheimer's disease.

Tau is a microtubule-associated protein, and abnormal tau function has been proposed to play a role in the development and progression of Alzheimer’s disease (AD). TPI-287 is an stabilizer of microtubule dynamics, and the stabilization of microtubules is hypothesized to compensate for the loss of tau function in AD. The purpose of this study is to determine the dose of TPI-287 that is safe and tolerable in people with mild to moderate AD, as well as to measure the properties and preliminary efficacy of TPI-287.

The purpose of this study is to determine the maximum tolerated dose of nimodipine as well as the safety and tolerability of oral nimodipine in progranulin mutation carriers.